SERCA2a activator A
CAS No. 2139330-34-8
SERCA2a activator A( Compound A )
Catalog No. M13416 CAS No. 2139330-34-8
SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 563 | In Stock |
|
| 5MG | 471 | In Stock |
|
| 10MG | 660 | In Stock |
|
| 25MG | 1036 | In Stock |
|
| 50MG | 1451 | In Stock |
|
| 100MG | 2027 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSERCA2a activator A
-
NoteResearch use only, not for human use.
-
Brief DescriptionSERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator.
-
DescriptionSERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN); binds to PLN (Kd=75 uM), attenuates its inhibition of SERCA2a; enhances systolic and diastolic functions in rat hearts.
-
In VitroSERCA2a activator 1 (Compound A) activates the Ca2+-dependent ATPase activity of cardiac sarcoplasmic reticulum (SR) vesicles but not that of skeletal muscle SR vesicles that lack phospholamban (PLN). The surface plasmon resonance assay reveals a direct interaction between SERCA2a activator 1 and PLN, suggesting that the binding of SERCA2a activator 1 to PLN attenuates its inhibition of SERCA2a, resulting in SERCA2a activation. SERCA2a activator 1 also increases the Ca2+ transients and contraction and relaxation of isolated adult rat cardiomyocytes. In isolated perfused rat hearts, the SERCA2a activator 1 enhances systolic and diastolic functions.
-
In VivoSERCA2a activator 1 (Compound A; 30mg/kg; intravenous injection; male Wistar rats) treatment significantly enhances the diastolic function in anesthetized normal rats. Animal Model:Male Wistar rats (7-8 weeks old) Dosage:30mg/kg Administration:Intravenous injection Result:Significantly enhanced the diastolic function in anesthetized normal rats.
-
SynonymsCompound A
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2139330-34-8
-
Formula Weight551.661
-
Molecular FormulaC32H29N3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (113.29 mM)
-
SMILESO=C(C1=CC(C(C=C2CC3=CC=CC=C3)=CN(CCCC)C2=O)=NC=C1)NS(=O)(C4=CC=C5C=CC=CC5=C4)=O
-
Chemical Name5'-benzyl-1'-butyl-N-(naphthalen-2-ylsulfonyl)-6'-oxo-1',6'-dihydro-[2,3'-bipyridine]-4-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kaneko M, et al. Eur J Pharmacol. 2017 Nov 5;814:1-8.
molnova catalog
related products
-
ω-Conotoxin MVIIC
Peptide neurotoxin; wide spectrum blocker of N, P and Q type calcium channels.
-
TTA-Q6
TTA-Q6, a selective T-type Ca2+ channel antagonist, exhibits potential antitumor and immunomodulatory activities for treating neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells, thereby inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress.
-
HUP30
HUP30 is a potent vasodilating agent. HUP30 can stimulate soluble guanylyl cyclase, activate K+ channels, and block extracellular Ca2+ influx.
Cart
sales@molnova.com